This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings
by Zacks Equity Research
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 37.4% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
by Zacks Equity Research
The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
by Ahan Chakraborty
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 60.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 21.43% and 17.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 12.50% and 0.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 22.37% and 2.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Equillium (EQ) delivered earnings and revenue surprises of 106.67% and 69.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 11.11% and 1.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.